

# TABLE OF CONTENTS

|  |    |  |     |
|--|----|--|-----|
| <b>Heart Failure I</b> .....   | 1  | <b>Heart Failure III</b> .....   | 93  |
| Heart Failure I Panel .....  | 3  | Heart Failure III Panel .....  | 95  |
| <b>Universal Definition and Classification of Heart Failure</b>  |    | <b>Cardiac Amyloidosis</b>   |     |
| <i>By Theodore J. Berei, Pharm.D., MBA, BCCP</i>   |    | <i>By Justin Arnall, Pharm.D., BCOP; and Mitchell E. Hughes, Pharm.D., BCPS, BCOP</i>  |     |
| Introduction .....   | 7  | Introduction .....   | 99  |
| Existing Definitions of HF .....   | 8  | Disease Identification, Workup, and Diagnosis .....  | 101 |
| New UHF Guidelines .....   | 10 | AL Amyloid (Acquired) .....  | 103 |
| Conclusion .....   | 12 | ATTR: ATTRv and ATTRwt .....   | 109 |
| References .....   | 13 | Supportive Therapy .....   | 112 |
| Other Comments .....   | 18 | Care Coordination and Practical Considerations .....   | 115 |
|  |    | Conclusion .....   | 115 |
|  |    | References .....   | 116 |
|  |    | Other Comments .....   | 121 |
| <b>New Therapies for Chronic Heart Failure</b>   |    | <b>Hypertrophic Cardiomyopathy</b>   |     |
| <i>By Jonathan D. Cicci, Pharm.D., BCPS, BCCP, CPP; and Megan M. Clarke, Pharm.D., BCPS, BCCP, CPP</i> |    | <i>By Kevin T Kissling, Pharm.D., BCPS</i>   |     |
| Introduction .....   | 19 | Overview of Hypertrophic Cardiomyopathy .....  | 123 |
| SGLT2i in Patients with Chronic HFrEF .....  | 19 | Management of Symptomatic Obstructive HCM With LVOTO .....   | 126 |
| SGLT2i in Patients at Risk of Developing HF .....  | 26 | Management of Symptomatic Nonobstructive HCM with Preserved LV Ejection Fraction .....   | 132 |
| Other Therapies for Chronic HF .....   | 28 | Management of Asymptomatic HCM .....   | 133 |
| Conclusion .....   | 32 | Selected Management Topics in HCM .....  | 134 |
| References .....   | 32 | Future Directions for Management of HCM .....  | 136 |
| Other Comments .....   | 37 | Conclusion .....   | 136 |
|  |    | References .....   | 136 |
|  |    | Other Comments .....   | 142 |
| <b>Heart Failure II</b> .....  | 39 | <b>Heart Failure IV</b> .....  | 143 |
| Heart Failure II Panel .....   | 41 | Heart Failure IV Panel .....   | 145 |
| <b>Optimal Management of Chronic Heart Failure During Hospitalization</b>                              |    | <b>Interactive Case: Systematic Reviews and Meta-analysis in Heart Failure</b>   |     |
| <i>By Joseph S. Van Tuyl, Pharm.D., BCCP</i>   |    | <i>By Diana M. Sobieraj, Pharm.D., FCCP; and Robert L. Page II, Pharm.D., MSPH, FCCP, FAHA, FHFSa, FASHP, BCGP, BCPS-AQ Cardiology</i> |     |
| Introduction .....   | 45 | Interactive Case: Systematic Reviews and Meta-analysis in Heart Failure .....  | 149 |
| Optimization of GDMT Before Hospital Discharge .....   | 46 | Hyperlink to Activity .....  | 150 |
| De-escalation or Discontinuation of GDMT During Hospitalization .....                                  | 51 | Other Comments .....   | 156 |
| Follow-Up After Hospital Discharge .....   | 56 |  |     |
| Conclusion .....   | 56 | <b>Interactive Case: Remote Patient Monitoring in Heart Failure</b>  |     |
| References .....   | 57 | <i>By Lucianne West, Pharm.D., BCCP; and Kathleen Faulkenberg, Pharm.D., BCPS</i>  |     |
| Other Comments .....   | 64 | Interactive Case: Remote Patient Monitoring in Heart Failure .....   | 157 |
|  |    | Hyperlink to Activity .....  | 157 |
|  |    | Other Comments .....   | 163 |
| <b>Palliative Care for Patients with Heart Failure</b>   |    |  |     |
| <i>By Diana Violanti, Pharm.D., BCPS; and Jennifer Pruskowski, Pharm.D., BCPS, BCGP, CPE</i>           |    |  |     |
| Introduction .....   | 65 |  |     |
| Pharmacist-Specific Primary Palliative Care Services .....   | 68 |  |     |
| Unique End of Life Scenarios in Advanced Heart Failure .....   | 83 |  |     |
| The Role of the Pharmacist in Palliative Care and Hospice .....  | 84 |  |     |
| References .....   | 84 |  |     |
| Other Comments .....   | 91 |  |     |